The estimated long-term clinical effects of BRCA testing and olaparib treatment of early breast cancer in the US population: a population impact model.

This study developed a decision-analytic model to evaluate the long-term impact of widespread germline BRCA testing and olaparib treatment in US patients with high-risk early breast cancer (eBC) eligible for olaparib.

The model estimated that in 2024, approximately 3,983 patients would be eligible for olaparib.

Compared to no testing or treatment, incorporating BRCA testing and olaparib therapy resulted in:

• 22% reduction in both metastatic and non-metastatic breast cancer recurrences
• 9% increase in life expectancy over a lifetime

Over 10 years, tens of thousands of recurrences could be prevented, with more than 78,000 life-years saved.

Sensitivity analyses confirmed the robustness of these clinical benefits.

These findings support the substantial value of routine BRCA testing and olaparib treatment in improving outcomes for high-risk eBC patients.